A dual-label time-resolved fluorescence immunoassay (TRFIA) for screening of Coronary atherosclerosis based on simultaneous detection of Lp-PLA2 and HsCRP

- Atherosclerosis is the underlying cause of most coronary events, and the conventional detection methods are complex and time-consuming.
- Here, a two-step dual-label TRFIA was developed for the simultaneous detection of Lp-PLA2 and hsCRP in a single run.
- The present dual-label TRFIA is sensitive, simple and inexpensive, and is a good alternative to the single-label diagnostic methods.

Atherosclerosis is the underlying cause of most coronary events. The conventional method for coronary atherosclerosis detection is morphological examination or coronary arterionyraphy. These methods are complex and time-consuming. In this study a two-step dual-label TRFIA was developed for the simultaneous detection of Lp-PLA2 and hsCRP in a single run. The performance of this assay was first evaluated using clinical serum samples, and then compared with commercialized kits. The sensitivity of this assay for Lp-PLA2 detection was 1 ng/mL (dynamic range, 0-1000 U/L), and the sensitivity for hsCRP detection was 1 mg/L (dynamic range, 1-1000 mg/L). High correlation coefficients (R) were obtained between the present dual-label TRFIA and commercially available kits(R = 0.99 for LP-PLA2 and hsCRP). The present dual-label TRFIA has high sensitivity, specificity, and accuracy in clinical sample analysis. It is a good alternative to the single-label diagnostic methods.